A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Inclusion Criteria:

• Have type 1 diabetes and on insulin treatment for at least one year prior toscreening

• Have an HbA1c value of 7.0% to 10.5% inclusive, at screening

• Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening

• Are of stable weight for at least 90 days prior to screening and agree to not startan intensive diet or exercise program during the study

Exclusion Criteria:

• Have experienced two or more events requiring hospitalization due to poor glucosecontrol (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180days prior to screening and until randomization.

• Have experienced one or more events of severe hypoglycemia during the period of 90days prior to screening and until randomization.

• Are currently receiving or planning to receive treatment for diabetic retinopathyand/or macular edema

• Have had chronic or acute pancreatitis

• Have used any weight loss drugs or alternative remedies, including herbal ornutritional supplements, within 90 days prior to screening